Peptides explained in plain language
Not medical advice
FDA-approvedCompounded · RxResearch-only

Growth hormone peptides and blood sugar

Peptides that raise growth hormone can push blood sugar up, which matters most if you have diabetes or prediabetes.

Key takeaways

  • Peptides that boost growth hormone may raise blood sugar.
  • The FDA-approved drug tesamorelin carries a warning about glucose intolerance and diabetes.
  • FDA flagged blood sugar concerns for GHRP-2 and GHRP-6, which remain on its safety-risk list.
  • If you have diabetes or prediabetes, involve your clinician before any of these products.

Peptides that raise growth hormone are marketed for muscle, fat loss, sleep and “anti-aging.” One side effect gets far less attention in those ads: they can affect your blood sugar. If you have diabetes, prediabetes or a family history of either, this is worth understanding.

Why growth hormone and blood sugar are linked

Growth hormone does many jobs in the body. One of them is helping keep blood sugar from dropping too low. It can work against some of insulin’s effects. So when a product pushes growth hormone higher, blood sugar can rise too.

Growth hormone peptides fall into a few groups. Some mimic the body’s growth hormone-releasing hormone, like sermorelin and tesamorelin. Others, called growth hormone-releasing peptides, include GHRP-2, GHRP-6 and ipamorelin. Ibutamoren, also called MK-677, is often sold alongside them, though it is not a peptide.

What the FDA-approved label says

Tesamorelin (Egrifta) is FDA-approved to reduce excess belly fat in adults with HIV and lipodystrophy. Because it is an approved drug, its label lays out known risks clearly.

That label warns that glucose intolerance or diabetes may develop. In clinical trials, more people taking tesamorelin developed blood sugar levels in the diabetes range than people taking a placebo. The label advises checking blood sugar before and during treatment. For people with diabetes, it also advises regular eye checks, since the drug raises a hormone called IGF-1.

That is what careful monitoring looks like for an approved product. Unapproved products come with no such guidance.

Get the weekly peptide brief

What changed in the rules, what new research says, and which claims to ignore. One email a week.

What the FDA flagged for unapproved peptides

GHRP-2, GHRP-6, ipamorelin, ibutamoren and kisspeptin-10 remain on the FDA’s list of substances that may present significant safety risks in compounding. In its notes, the FDA cited reports of a higher insulin need to control blood sugar with GHRP-2, and decreased insulin sensitivity with GHRP-6.

Growth hormone-releasing peptides may also cause fluid retention. In theory, they could encourage existing tumors to grow.

Many of these products are sold online as “research chemicals.” They aren’t made under drug-quality rules. The dose on the label may not match what is in the vial, which makes blood sugar effects even harder to predict.

Who should be especially careful

  • People with type 1 or type 2 diabetes, or prediabetes
  • People taking insulin or other diabetes medicines, whose doses may need changes
  • People with a family history of diabetes
  • Anyone with a current or past cancer

Signs of high blood sugar can include more thirst, frequent urination, blurry vision and tiredness. If you notice these, contact your clinician.

The bottom line

Growth hormone peptides can nudge blood sugar up, and the approved drug in this group carries a clear warning about it. Unapproved versions add uncertainty about what you are actually taking. If you are considering any growth hormone product, talk with your clinician first, and make sure blood sugar is part of the conversation.

This article is for general education and isn’t medical or legal advice. It was written with AI assistance and may contain errors, so check anything that matters against the sources above and with a qualified healthcare professional before starting, stopping or changing any treatment. Why we say this.

Chris Janowski
About the author

Chris Janowski, owner and editor in chief

Chris Janowski is the editor in chief of Peptide Consumer Center. He started the site to give people a plain-language, well-sourced place to learn what peptides are, how they’re regulated and what the evidence actually says. Articles are written with AI assistance and published under his name.

Peptide Consumer Center is owned by Chris Janowski, who also owns PureVitaX, an online store that sells peptides, including several covered on this site. We link to PureVitaX, and Chris benefits when you buy there. Disclosures.